Hypermutated tumours across 11 cancer types show three distinct immune subtypes
- 1 May 2021
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 148, 230-238
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81802883)
- Fundamental Research Funds for the Central Universities (2018FZA7012)
- Fundamental Research Funds for the Central Universities
This publication has 23 references indexed in Scilit:
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cellsNature, 2018
- Tumor Purity as an Underlying Key Factor in GliomaClinical Cancer Research, 2017
- Converting Cold into Hot Tumors by Combining ImmunotherapiesCell, 2017
- Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast CarcinomasCancer Research, 2017
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeJournal of Clinical Investigation, 2017
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic FactorsImmunity, 2016
- Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating LymphocytesCancer Immunology Research, 2016
- Pan-cancer analysis of the extent and consequences of intratumor heterogeneityNature Medicine, 2015
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomesNature Medicine, 2015
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic ValuePLOS Medicine, 2013